论文信息 - A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. - 字舞流文

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.

I. Vergote | Jung-Min Lee | N. Colombo | K. Credille | P. Konstantinopoulos | R. Shapira-Frommer | Xuejing Wang | Rowan E Miller | Jung-Yun Lee | S. McNeely | B. Gao | A. Lin | S. Young | Jung-Yun Lee | S. Mcneely